Skip to main content
. Author manuscript; available in PMC: 2014 Aug 26.
Published in final edited form as: Radiat Res. 2014 Jul 3;182(2):211–218. doi: 10.1667/RR13495.1

FIG. 2.

FIG. 2

Prior ipsilateral breast irradiation increases complete response rate to HER2-targeted dendritic cell (DC) vaccine. Patients with HER2+ breast ductal carcinoma in situ (DCIS) were treated with HER2-pulsed type 1-polarized DC vaccine prior to surgery. Residual disease at the time of surgery was assessed, and percentage of patients displaying complete response (CR) is shown. ER-independent patients who had prior ipsilateral breast irradiation showed particularly marked tumor regression compared with ER-dependent patients or those who had received no prior irradiation or prior irradiation to the contralateral breast only.